Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
Start free trial
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
Special Offer: Just $199
×
S&P 500   3,973.01 (+0.23%)
DOW   33,912.37 (+0.19%)
QQQ   282.07 (-0.23%)
AAPL   143.38 (-0.58%)
MSFT   240.66 (-0.45%)
META   109.54 (+0.70%)
GOOGL   95.11 (-0.98%)
AMZN   93.08 (-0.93%)
TSLA   183.41 (+0.27%)
NVDA   157.93 (-0.21%)
NIO   10.78 (+6.52%)
BABA   79.90 (+5.30%)
AMD   73.76 (+0.78%)
T   18.86 (+0.21%)
MU   56.08 (+0.59%)
CGC   3.43 (+0.88%)
F   13.78 (+0.36%)
GE   85.46 (-0.01%)
DIS   95.59 (-0.10%)
AMC   7.31 (-0.27%)
PYPL   80.03 (+0.13%)
PFE   49.54 (-0.06%)
NFLX   279.72 (-0.52%)
S&P 500   3,973.01 (+0.23%)
DOW   33,912.37 (+0.19%)
QQQ   282.07 (-0.23%)
AAPL   143.38 (-0.58%)
MSFT   240.66 (-0.45%)
META   109.54 (+0.70%)
GOOGL   95.11 (-0.98%)
AMZN   93.08 (-0.93%)
TSLA   183.41 (+0.27%)
NVDA   157.93 (-0.21%)
NIO   10.78 (+6.52%)
BABA   79.90 (+5.30%)
AMD   73.76 (+0.78%)
T   18.86 (+0.21%)
MU   56.08 (+0.59%)
CGC   3.43 (+0.88%)
F   13.78 (+0.36%)
GE   85.46 (-0.01%)
DIS   95.59 (-0.10%)
AMC   7.31 (-0.27%)
PYPL   80.03 (+0.13%)
PFE   49.54 (-0.06%)
NFLX   279.72 (-0.52%)
S&P 500   3,973.01 (+0.23%)
DOW   33,912.37 (+0.19%)
QQQ   282.07 (-0.23%)
AAPL   143.38 (-0.58%)
MSFT   240.66 (-0.45%)
META   109.54 (+0.70%)
GOOGL   95.11 (-0.98%)
AMZN   93.08 (-0.93%)
TSLA   183.41 (+0.27%)
NVDA   157.93 (-0.21%)
NIO   10.78 (+6.52%)
BABA   79.90 (+5.30%)
AMD   73.76 (+0.78%)
T   18.86 (+0.21%)
MU   56.08 (+0.59%)
CGC   3.43 (+0.88%)
F   13.78 (+0.36%)
GE   85.46 (-0.01%)
DIS   95.59 (-0.10%)
AMC   7.31 (-0.27%)
PYPL   80.03 (+0.13%)
PFE   49.54 (-0.06%)
NFLX   279.72 (-0.52%)
S&P 500   3,973.01 (+0.23%)
DOW   33,912.37 (+0.19%)
QQQ   282.07 (-0.23%)
AAPL   143.38 (-0.58%)
MSFT   240.66 (-0.45%)
META   109.54 (+0.70%)
GOOGL   95.11 (-0.98%)
AMZN   93.08 (-0.93%)
TSLA   183.41 (+0.27%)
NVDA   157.93 (-0.21%)
NIO   10.78 (+6.52%)
BABA   79.90 (+5.30%)
AMD   73.76 (+0.78%)
T   18.86 (+0.21%)
MU   56.08 (+0.59%)
CGC   3.43 (+0.88%)
F   13.78 (+0.36%)
GE   85.46 (-0.01%)
DIS   95.59 (-0.10%)
AMC   7.31 (-0.27%)
PYPL   80.03 (+0.13%)
PFE   49.54 (-0.06%)
NFLX   279.72 (-0.52%)
NASDAQ:CGIX

Cancer Genetics - CGIX Stock Forecast, Price & News

$1.30
-0.02 (-1.52%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.28
▼
$1.36
50-Day Range
$0.38
▼
$4.61
52-Week Range
$2.11
▼
$17.50
Volume
8,474 shs
Average Volume
2.44 million shs
Market Capitalization
$5.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CGIX stock logo

About Cancer Genetics (NASDAQ:CGIX) Stock

Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.

Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

CGIX Stock News Headlines

November 22, 2022 | americanbankingnews.com
Cancer Genetics (NASDAQ:CGIX) Now Covered by Analysts at StockNews.com
November 15, 2022 | markets.businessinsider.com
Geneseeq Publishes Promising Early Lung Cancer Detection Results in AJRCCM
November 14, 2022 | msn.com
Cancer of the Appendix: Very Rare, But Genes May Play Role
November 14, 2022 | msn.com
Scientists Discover X Chromosomes Being 'Silenced' in Male Cancer Cells
November 14, 2022 | msn.com
Genetic variant may be linked to cancer of the appendix
November 11, 2022 | msn.com
Scientists trial using gene editing to 'reprogramme' immune systems to target cancer
November 8, 2022 | businessinsider.com
A woman with a rare set of genetic mutations got cancer 5 times by the time she was 36
November 8, 2022 | apnews.com
Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company
November 4, 2022 | benzinga.com
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
September 27, 2022 | marketwatch.com
New standards set for Genomics in Cancer Care Market grow at 17.37% CAGR| 116 Report Pages
September 21, 2022 | marketwatch.com
Compacted Graphite Iron (CGI) Market Growth, Size, Share, 2022 Top Leading Countries, Trends, Demand, Challenges and Global Forecast 2027
September 20, 2022 | usnews.com
Water.org Unveils $1 Billion Plan for Water Access at CGI
September 17, 2022 | msn.com
10 Once-Great CGI Scenes That Haven't Aged Well
September 13, 2022 | msn.com
10 Worst-Looking CGI Characters, According to Reddit
September 13, 2022 | msn.com
5 Moments in Christopher Nolan Movies That Actually Aren’t CGI
September 13, 2022 | technews.tmcnet.com
Bluestar Genomics Presents Data on New Applications of its Epigenomic Cancer Detection Platform
September 9, 2022 | msn.com
Pinocchio, the Disney movie fusing live-action Tom Hanks and CGI, is a deft spin on a classic
September 9, 2022 | msn.com
Marvel seemingly changes Thor: Love and Thunder CGI for Disney Plus release
September 9, 2022 | msn.com
Marvel secretly changes CGI in much-derided Thor: Love and Thunder scene – but fans say it ‘looks even worse’
September 9, 2022 | msn.com
Thor: Love And Thunder Updates Infamous Floating Head CGI, Fans Still Hate It
September 9, 2022 | cnet.com
'Thor: Love and Thunder' Fans Notice CGI Fix for Disney Plus
September 6, 2022 | msn.com
Criminal Minds Morgan Actor Recalls CGI Goatee Prank
September 5, 2022 | msn.com
She-Hulk BTS Photos Show Off Pre-CGI Twerking With Megan Thee Stallion
September 4, 2022 | msn.com
Was Prey's Divisive Predator CGI Really Necessary?
August 31, 2022 | markets.businessinsider.com
CGI Federal readies customers for G-Invoicing federal mandate with new versions of its Momentum® ERP solution
See More Headlines
Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGIX
CUSIP
N/A
CIK
N/A
Web
www.cancergenetics.com
Phone
(201) 479-1357
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,085,000
Free Float
N/A
Market Cap
$5.31 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • John A. Roberts
    President, Chief Executive Officer & Director
  • Andrew D. C. LaFrence
    Chief Operating & Financial Officer
  • Robert T. Fremeau
    Chief Scientific Officer
  • Ping Yeh
    Director & Chief Innovation Officer
  • Ralf Brandt
    President-Discovery & Early Development Services

Key Competitors

View All Competitors













CGIX Stock - Frequently Asked Questions

How have CGIX shares performed in 2022?

Cancer Genetics' stock was trading at $1.12 at the beginning of the year. Since then, CGIX stock has increased by 16.1% and is now trading at $1.30.
View the best growth stocks for 2022 here.

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Activision Blizzard (ATVI), Ford Motor (F), Gilead Sciences (GILD), CymaBay Therapeutics (CBAY), Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD).

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?

Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $1.30.

How much money does Cancer Genetics make?

Cancer Genetics (NASDAQ:CGIX) has a market capitalization of $5.31 million.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 State Rt 17 Fl 2, Rutherford, New Jersey 07070-2597. The official website for the company is www.cancergenetics.com. The company can be reached via phone at (201) 479-1357.

This page (NASDAQ:CGIX) was last updated on 11/29/2022 by MarketBeat.com Staff